The company had $125.6M in cash, cash equivalents, and short-term investments as of September 30, 2023. “We are looking forward to sharing topline results of our pivotal STRIDE study in December,” said CEO GregoryFlesher. “In addition, we continue to be encouraged by the high participation rate in our STRIDE AHEAD open-label extension study, and are happy to announce enrollment of our first patient with PMM due to nuclear DNA defect in this ongoing trial. This is a very exciting time for the Reneo team and we want to thank our clinicians, patients, and stakeholders for supporting the mavodelpar development program.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RPHM:
- Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
- Jefferies healthcare/biotech analysts hold an analyst/industry conference call
- Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
- Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
- Reneo Pharmaceuticals announces poster presentation on mavodelpar